Premium
Janus‐like effects of type I interferon in autoimmune diseases
Author(s) -
Axtell Robert C.,
Raman Chander
Publication year - 2012
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.2012.01131.x
Subject(s) - multiple sclerosis , immunology , autoimmunity , autoimmune disease , disease , neuromyelitis optica , interferon , experimental autoimmune encephalomyelitis , medicine , interferon type i , population , immune system , antibody , pathology , environmental health
Summary: In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are non‐responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro‐inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom